BioSpace News Archive

Year

• 2005
• 2006
• 2007
• 2008
• 2009
• 2010
• 2011
• 2012
• 2013
• 2014
• 2015
• 2016
• 2017
• 2018
• 2019
• 2020
• 2021
• 2022
• 2023
• 2024
• 2025
• 2026

Month

• January
• February
• March
• April
• May
• June
• July
• August
• September
• October
• November
• December

Day

• 2
• 3
• 4
• 5
• 6
• 9
• 10
• 11
• 12
• 13
• 14
• 15
• 16
• 17
• 18
• 19
• 20
• 21
• 23
• 24
• 25
• 26
• 27
• 28
• 29
• 30
• 31

• 

  Business

  Alpine Immune Sciences and Kite Extend Research Term of Collaboration to Create Next-Generation CAR-T and TCRs

  The research collaboration and license agreement was originally initiated in October 2015.

  October 23, 2017

   · 

  3 min read
• 

  FDA

  FDA Approves AstraZeneca’s New Easy-to-Use, Once-weekly BYDUREON BCise Injectable Medicine for Patients with Type-2 Diabetes

  BYDUREON BCise has a unique, continuous-release microsphere delivery system designed to provide consistent therapeutic levels of the active ingredient.

  October 23, 2017

   · 

  8 min read
• Business

  Biogen and Eisai Expand Alzheimer’s R&D Collaboration

  Under the deal, Eisai has exercised its option to co-develop and co-promote aducanumab, Biogen’s investigational anti-amyloid beta antibody for patients with Alzheimer’s disease.

  October 23, 2017

   · 

  10 min read
• Lexington Biosciences Receives HeartSentry Trial Units

  Lexington Biosciences, Inc., a development-stage medical device company, is pleased to announce receipt of the first HeartSentry human-use units from its manufacturer.

  October 23, 2017

   · 

  4 min read
• Drug Development

  Enanta Pharmaceuticals Announces Positive Phase I a/b Clinical Results for Its Lead FXR Agonist, EDP-305

  Enanta Pharma announced positive results from its Phase 1 clinical study of EDP-305, Enanta’s lead FXR agonist for non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC).

  October 23, 2017

   · 

  7 min read
• Biotech Beach

  Regen BioPharma Begins Program to Determine the 3-Dimensional Crystal Structure of NR2F6

  Regen BioPharma and (OTCQB: RGBPP) has begun a program to determine the 3-dimensional structure of NR2F6 both with and without the Company’s proprietary small molecule drugs bound to it.

  October 23, 2017

   · 

  2 min read
• Drug Development

  Eiger Announces Positive Phase II Interim 24-Week Data with Pegylated Interferon Lambda in Hepatitis Delta Virus Infection at the AASLD Meeting

  Eiger BioPharma today announced positive interim 24-week data with pegylated interferon lambda in the Phase II LIMT HDV Study presented at the AASLD meeting in Washington DC.

  October 23, 2017

   · 

  8 min read
• Business

  Henry Schein to Webcast Third Quarter 2017 Conference Call on Monday, November 6, 2017 at 10:00 A.M. ET

  Henry Scheinl announced today that it will release its third quarter 2017 financial results before the stock market opens on Monday, November 6, 2017, and will provide a live webcast of its earnings conference call on the same day beginning at 10:00 a.m. Eastern time.

  October 23, 2017

   · 

  2 min read
• Business

  Intrexon and Arch Pharmalabs Collaborate on Fermentative Production of an API to Replace Existing Process Sourced from Animals

  Intrexon and Arch Pharmalabs today announced they have entered into an exclusive collaboration to develop microbial strains for fermentation-based production of an API currently sourced from animals.

  October 23, 2017

   · 

  5 min read
• Business

  Almac Group Announces Successful MHRA Inspection at Charnwood Facilities

  This successful inspection provides Almac Pharma Services with the necessary licenses to develop, manufacture and pack non-potent and potent, solid oral drug products for clinical trials and commercial supply at the Charnwood site.

  October 23, 2017

   · 

  2 min read